Pfizer and AstraZeneca: Marketing an Acquisition (A) Harvard Case Solution & Analysis

In the year 2014, Pfizer introduced a cordial procurement of AstraZeneca, but the AstraZeneca board combated due to pricing and strategy concerns. Was it great for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced problems in growing sales because of the challenges of producing new drugs. Over earlier decade or more, Pfizer had chased acquisitions as a method to acquire new medications, increase in sales, and to reduce prices by combining operations and cutting staff.

Lately, AstraZeneca had significantly strengthened its pipeline of potential new drugs and its particular board believed it was in strong position to move alone. The CEO of the company also hinted that an acquisition would be disruptive to its drug development predicaments and delay new drugs entering market. U.K. politicians displayed anxieties over downsizing and job losses in the economically important pharmaceutical sector. The case enables readers to explore who advantages from a possible acquisition (shareholders, employees, drug consumers) and which of these stakeholders should be considered when choosing an acquisition.

PUBLICATION DATE: September 24, 2014 PRODUCT #: 515007-PDF-ENG

This is just an excerpt. This case is about SALES & MARKETING

Pfizer and AstraZeneca: Marketing an Acquisition (A) Case Solution Other Similar Case Solutions like

Pfizer and AstraZeneca: Marketing an Acquisition (A)

Share This